Patients who received gilteritinib demonstrated a significantly higher CR/Cri rate (34% vs. 15%), longer median OS (9.3 months vs. 5.6 months), and longer post-transplant survival (16.2 months vs. 8.4 months) as compared to those who received salvage chemotherapy, resulting in FDA approval for adults with r/r, FLT3-mutated AML [90]. The gene discussed is FLT3; the disease is acute myeloid leukemia.